Daily curated COVID-19 literature
WP11 - The objective of this work package is to respond to requests concerning the current scientific knowledge on SARS-CoV-2. Based on the latest scientific literature the team will compile findings and give advice when needed
9 publications
Journal
2020-05-29
Proteomic and Metabolomic Characterization of COVID-19 Patient Sera
Expert Summary: The authors performed proteomic and metabolomic profiling of sera from 46 COVID-19 patients, from which 13 were severe, and respective conrols. There were olecular changes in the sera of COVID-19 patients compared to other groups, mainly concerning dysregulation of macrophage, platelet degranulation and complement system pathways. Through the sera, it can also be observed great metabolic suppression.
2020-05-19
Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells
Expert Summary: The authors identify 14 SARS-CoV-2 neutralizing antibodies using high-throughput single-cell RNA and VDJ sequencing of antigen-enriched B cells from 60 convalescent patients. The most potent antibody has proved strong therapeutic and prophylactic efficacy in hACE2-transgenic mice infected by SARS-CoV-2.
2020-05-18
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Expert Summary: The authors offer an in-depth analysis of the transcriptional response to SARS-CoV-2 compared with other respiratory viruses. They propose that reduced innate antiviral defenses coupled with exuberant inflammatory cytokine production are the defining and driving features of COVID-19.
Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells
Expert Summary: The authors report the rapid identification of SARS-CoV-2 neutralizing antibodies by high-throughput single-cell RNA and VDJ sequencing of antigen-enriched B cells from 60 convalescent patients. One of the neutralizing antibodies also displayed strong therapeutic and prophylactic efficacy in SARS-CoV-2-infected hACE2-transgenic mice.
2020-05-15
Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals
Expert Summary: Using HLA class I and II predicted peptide ‘megapools’, circulating SARS-CoV-2−specific CD8+ and CD4+ T cells were identified in ∼70% and 100% of COVID-19 convalescent patients, respectively. T cell responses are focused not only on spike but also on M, N and other ORFs. There might be cross-reactive T cell recognition between circulating ‘common cold’ coronaviruses and SARS-CoV-2.
2020-05-08
Host-viral infection maps reveal signatures of severe COVID-19 patients
Expert Summary: The authors created a computational method that scans unmapped scRNA-seq data for the presence of viral RNA, enabling transcriptional cell sorting of infected versus bystander cells. Applying Viral-Track to Bronchoalveloar-Lavage samples from severe and mild COVID-19 patients reveals a dramatic impact of the virus on the immune system of severe patients compared to mild cases. Coinfection of SARS-Cov-2 and hMPV affects monocytes and dampen interferon response.
2020-05-06
Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies
Expert Summary: The authors describe the isolation of single-domain antibodies (VHHs) from a llama immunized with prefusion-stabilized coronavirus spikes. These VHHs neutralize MERS-CoV or SARS-CoV-1 S pseudotyped viruses, respectively. A cross-reactivity between the SARS-CoV-1 S-directed VHH and SARS-CoV-2 S was shown and the authors demonstrates that this cross-reactive VHH neutralizes SARS-CoV-2 S pseudotyped viruses as a bivalent human IgG Fc-fusion. These data provide a molecular basis for the neutralization of pathogenic betacoronaviruses by VHHs and suggest that these molecules may serve as useful t...
2020-05-04
Imbalanced hostresponse to SARS-CoV-2 drives development of COVID-19
Expert Summary: The authors perform an in-depth analysis of the transcriptional response to SARS-CoV-2. The team analyzed primary cells, animal models of SARS-CoV-2 infections and COVID-19 patients and all revealed an exacerbated inflammatory response. This response is defined by low levels of Type I and III interferons, in contrast to elevated chemokines and high expression of IL-6. In summary, the authors propose that reduced innate antiviral defenses coupled with a heightened inflammatory cytokine production define COVID-19 clinical features.
